Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®) / Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade®)
Rev. méd. Chile
;
134(3): 326-331, mar. 2006. tab, graf
Article
in Spanish
| LILACS
| ID: lil-426099
ABSTRACT
Background:
Psoriasis has a moderate or severe course in 25% of patients, requiring systemic therapy that is not always successful. Infliximab is a human-murine monoclonal anti tumor necrosis alpha (TNF-a) antibody. This mediator has a role in the pathogenesis of psoriasis.Aim:
To evaluate the use of infliximab in psoriatic patients resistant to conventional therapies. Material andMethods:
An open prospective study including eight patients with extensive plaque or erythrodermic psoriasis. They were treated with infliximab 5 mg/kg/dose on weeks 0,2 and 6. Patients were evaluated every 2 weeks for a median lapse of 50.1 weeks. Physical examination, PASI scores (Psoriasis Area Severity Index) and a photographic control, were done in each visit.Results:
All the patients responded in the first 10 weeks of follow-up. The mean reduction in PASI score was 86.6%. Six patients received fourth infusion of infliximab at 37.3 weeks, on average. The most common adverse events were pruritus and headache.Conclusions:
This group of patients with extensive plaque or erythrodermic psoriasis resistant to conventional therapies, had a good response to infliximab.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Psoriasis
/
Dermatologic Agents
/
Antibodies, Monoclonal
Type of study:
Observational study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2006
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Universidad de Chile/CL
Similar
MEDLINE
...
LILACS
LIS